EverPoint Asset Management’s Celgene Corp CELG Stock Holding History

EverPoint Asset Management’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-100,000	Closed	-$8.59M	–	652
2014 Q2	$8.59M	Buy	+100,000	New	+$7.6M	0.18%	172

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EverPoint Asset Management's CELG Position: Q4 2016 in Review

EverPoint Asset Management increased its Celgene Corp (CELG) stake by 169% in Q4 2016, buying an estimated $50M and bringing the position to 714,000 shares worth $82.6M. The position accounts for 1.54% of the portfolio, ranked #9.

EverPoint Asset Management first reported a position in CELG in Q2 2014 and has held it in 8 quarters since. 1,375 funds tracked by Wall St. Rank hold CELG as of Q4 2016.

EverPoint Asset Management held 714,000 shares of Celgene Corp worth $82.6M as of Q4 2016.
EverPoint Asset Management bought 449,000 Celgene Corp shares in Q4 2016, an estimated $50M.
Celgene Corp made up 1.54% of EverPoint Asset Management's portfolio in Q4 2016, its #9 holding.
EverPoint Asset Management first reported a position in Celgene Corp in Q2 2014 and has held it in 8 quarters since.
1,375 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.